Tirzepatide (Mounjaro)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CN
  • Type 2 diabetes (weight-management approval followed in July 2024 per trade press)
Product first approved 2024yicaiglobal.com
JP
  • Mounjaro: type 2 diabetes
Product first approved 2022pj.jiho.jp
EU
  • Mounjaro: type 2 diabetes; the EPAR also lists weight management (adjunct to diet and activity)
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Type 2 Diabetes
NCT06246799 · The University of Texas Health Science Center at San Antonio
2024-11-07 – 2029-06-30 · Type 2 Diabetes (Adult Onset)
What this study did
NCT05963022 · Eli Lilly and Company
2023-08-21 – 2024-10-09 · Type 2 Diabetes
What this study did
NCT05691712 · Eli Lilly and Company
2023-02-05 – 2024-07-01 · Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
What this study did
NCT04093752 · Eli Lilly and Company
2019-12-09 – 2021-11-24 · Type 2 Diabetes
What this study did
NCT03861052 · Eli Lilly and Company
2019-05-07 – 2021-03-31 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07165028 · Eli Lilly and Company
2025-10-15 – 2032-08 · Metabolic Dysfunction-Associated Steatotic Liver Disease
What this study did
NCT07671248 · McMaster University
2026-08-01 – 2028-07-31 · Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
What this study did
NCT06630585 · University of Bern
2025-02-14 – 2026-06 · Type 1 Diabetes (T1D)
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT07284511 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2026-05-19 – 2029-01 · Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
What this study did
NCT07734792 · yifang zhu
2026-09-26 – 2028-07-31 · Acute Ischemic Stroke (AIS)
What this study did
Phase 2 (25)
Type 2 Diabetes
NCT03131687 · Eli Lilly and Company
2017-05-24 – 2018-08-01 · Type 2 Diabetes Mellitus
What this study did
NCT03311724 · Eli Lilly and Company
2017-10-19 – 2018-04-24 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07825857 · University of Texas Southwestern Medical Center
2026-10-23 – 2031-08 · Methamphetamine Use Disorder
What this study did
NCT07946315 · Brigham and Women's Hospital
2027-01-01 – 2030-05-01 · Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri, Papilledema
What this study did
NCT07527910 · Regeneron Pharmaceuticals
2026-05-22 – 2030-03-15 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
What this study did
NCT07091734 · University of Michigan
2025-09-08 – 2029-09 · Lipodystrophy, Partial
What this study did
NCT06939088 · Anders Fink-Jensen, MD, DMSci
2025-05-05 – 2028-12-31 · Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders, Schizophrenia and Disorders With Psychotic Features, Schizophrenia and Schizophrenia Spectrum Psychosis, Schizophrenia
What this study did
NCT07573163 · Alaa Sada
2026-07-27 – 2028-12-31 · Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
What this study did
NCT07468552 · National Institute on Drug Abuse (NIDA)
2026-11-15 – 2028-11-15 · Cannabis Use Disorder
What this study did
NCT07602699 · University of Southern California
2026-06-05 – 2028-09 · Smoking Cessation, Smoking Behaviors
What this study did
NCT07906041 · Atria Research and Global Health Institute (ARGHI)
2026-10 – 2028-09 · Longevity, Preventive Medicine, Biological Ageing
What this study did
NCT06976853 · Washington University School of Medicine
2025-05-13 – 2028-08 · Crohn Disease (CD)
What this study did
NCT07265752 · Brigham and Women's Hospital
2027-03-01 – 2028-06-30 · Cannabis Use Disorder
What this study did
NCT07734870 · Johns Hopkins University
2026-09-15 – 2028-05-25 · Central Centrifugal Cicatricial Alopecia (CCCA)
What this study did
NCT07676331 · Universitaire Ziekenhuizen KU Leuven
2026-08-01 – 2028-05-01 · Hormone-receptor-positive Breast Cancer, Early Breast Cancer
What this study did
NCT07202247 · City of Hope Medical Center
2025-11-05 – 2028-04-09 · Prostate Carcinoma, Recurrent Prostate Carcinoma
What this study did
NCT07220473 · The University of Texas Medical Branch, Galveston
2026-02-27 – 2028-01 · Aging, LONGEVITY 1
What this study did
NCT07605247 · Rutgers, The State University of New Jersey
2026-06-01 – 2028-01 · Endometrial Cancer
What this study did
NCT06820281 · Victor Chang Cardiac Research Institute
2026-07-07 – 2027-12-31 · Type 1 Diabetes Mellitus
What this study did
NCT06651177 · T. John Winhusen, PhD
2026-01-29 – 2027-10-31 · Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
What this study did
NCT07046819 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2026-06-11 – 2027-07-30 · Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder
What this study did
NCT06727331 · Brigham and Women's Hospital
2025-09-15 – 2027-07-01 · Alcohol Use Disorder (AUD)
What this study did
The Long COVID Treatment Trialactive not recruiting
NCT07128082 · Scripps Translational Science Institute
2025-10-30 – 2026-12 · Long COVID
What this study did
NCT05659368 · Ospedale San Raffaele
2024-01-01 – 2024-12 · Wolfram Syndrome
What this study did
NCT04166773 · Eli Lilly and Company
2019-11-19 – 2024-01-10 · Nonalcoholic Steatohepatitis
What this study did
Phase 1 (19)
Type 2 Diabetes
NCT04050553 · Eli Lilly and Company
2020-02-24 – 2022-01-25 · Diabetes Mellitus, Type 2, Hypoglycemia
What this study did
NCT04235959 · Eli Lilly and Company
2020-10-21 – 2021-08-17 · Diabetes Mellitus, Type 2
What this study did
NCT03951753 · Eli Lilly and Company
2019-06-28 – 2021-04-08 · Diabetes Mellitus, Type 2
What this study did
NCT03322631 · Eli Lilly and Company
2017-11-15 – 2018-11-28 · Type 2 Diabetes Mellitus
What this study did
NCT02759107 · Eli Lilly and Company
2016-05-11 – 2017-06-26 · Healthy, Type 2 Diabetes Mellitus (T2DM)
What this study did
Other / comorbidity
NCT07559500 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2026-05-20 – 2031-12-31 · Alcohol Use Disorder (AUD)
What this study did
NCT07782359 · University of Chicago
2026-10-22 – 2030-06 · Lung Cancer
What this study did
NCT07095517 · Massachusetts General Hospital
2026-02-24 – 2028-12-31 · Colorectal Cancer Prevention, Colorectal Adenoma
What this study did
NCT07812636 · Milton S. Hershey Medical Center
2026-11-01 – 2028-08-01 · Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
What this study did
NCT06890611 · Eli Lilly and Company
2025-03-25 – 2025-09-26 · Healthy
What this study did
NCT05978713 · Eli Lilly and Company
2023-07-31 – 2024-03-12 · Healthy
What this study did
NCT05810597 · Eli Lilly and Company
2023-04-03 – 2023-07-17 · Healthy
What this study did
NCT04172987 · Eli Lilly and Company
2020-02-26 – 2021-02-09 · Healthy
What this study did
NCT04311424 · Eli Lilly and Company
2020-07-28 – 2020-10-02 · Healthy
What this study did
NCT03940742 · Eli Lilly and Company
2019-07-22 – 2020-09-22 · Hepatic Insufficiency
What this study did
NCT04050670 · Eli Lilly and Company
2019-09-13 – 2020-04-03 · Healthy
What this study did
NCT04004988 · Eli Lilly and Company
2019-08-19 – 2019-12-16 · Healthy
What this study did
NCT03482024 · Eli Lilly and Company
2018-03-30 – 2019-08-19 · Renal Insufficiency, End Stage Renal Disease
What this study did
NCT03375463 · Eli Lilly and Company
2017-12-19 – 2018-12-27 · Healthy
What this study did
Phase 4 (12)
Atherosclerotic Cardiovascular Disease
NCT05708859 · Matthew J. Budoff
2024-01-02 – 2026-05 · Type II Diabetes, Atherosclerosis
What this study did
Type 2 Diabetes
NCT06657209 · Stanford University
2025-01-13 – 2027-12-15 · Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
What this study did
NCT05433584 · Eli Lilly and Company
2022-08-01 – 2027-11 · Type 2 Diabetes
What this study did
NCT05553093 · Nanjing First Hospital, Nanjing Medical University
2022-03-15 – 2027-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT06635057 · Eli Lilly and Company
2024-10-11 – 2026-04-15 · Type 2 Diabetes
What this study did
NCT05564039 · Eli Lilly and Company
2022-11-30 – 2024-08-12 · Type 2 Diabetes
What this study did
NCT05706506 · Eli Lilly and Company
2023-03-08 – 2023-10-31 · Type 2 Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07191873 · Duke University
2026-08-25 – 2028-08 · Idiopathic Intracranial Hypertension (IIH)
What this study did
NCT07706088 · Post Graduate Institute of Medical Education and Research, Chandigarh
2026-07 – 2028-07-01 · Neuropathy, Small Fiber, Diabete Mellitus
What this study did
NCT07483801 · Cambridge University Hospitals NHS Foundation Trust
2026-03 – 2028-04 · Cardiovascular Diseases
What this study did
NCT07756359 · University of North Carolina, Chapel Hill
2027-01-04 – 2027-09 · Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, Inflammatory
What this study did
NCT06774079 · University of Miami
2025-03-05 – 2027-03-05 · Crohn Disease
What this study did
Early phase / not applicable (3)
Type 2 Diabetes
NCT07303556 · Nazarbayev University
2024-12-18 – 2026-11-01 · Heart Failure, Diabete Type 2, Arterial Hypertension
What this study did
NCT05990374 · Nanjing First Hospital, Nanjing Medical University
2023-08-01 – 2024-01-01 · Diabetes
What this study did
Other / comorbidity
NCT06301256 · Florida Academic Centers Research and Education, LLC
2024-03-11 – 2025-03-11 · Hidradenitis Suppurativa
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Phase 2 (1)
Type 2 Diabetes
NCT07796477 · CSPC Ouyi Pharmaceutical Co., Ltd.
2026-11-06 – 2027-10-19 · T2DM (Type 2 Diabetes Mellitus)
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tirzepatide (Mounjaro): this drugApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Tirzepatide (Zepbound)
Approved(overall)
PeptideGLP-1/GIP receptor (dual)
Reliable signal(overall)
No reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Brenipatide
Phase 3(overall)
PeptideGLP-1/GIP receptor (dual)
not yet graded(overall)
No reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication
THDBH120
Phase 2(overall)
PeptideGLP-1/GIP receptor (dual)
Weak signal(overall)
No reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 1/2Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Weak signal
NCT03381287: Day 28, 2000 mg/day (highest dose) vs placebo: total cholesterol -8.2% (P=0.0004); LDL-C -10.4% (P=0.0006). Lower doses (500 mg, 1000 mg) did not reach significance.
KP405
Phase 1(overall)
PeptideGLP-1/GIP receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 66 furthest-along competitors are listed; 61 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(36 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tirzepatide (Mounjaro) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Long COVIDActive not recruiting
Est. primary completion 2026-12 · NCT07128082 · CT.gov ↗
What to watch
2027 (11)
March 2027 (3)
Phase 2Alcohol Use Disorder (AUD)Recruiting
Est. primary completion 2027-03-01 · NCT06727331 · CT.gov ↗
What to watch
Phase 4Crohn DiseaseActive not recruiting
Est. primary completion 2027-03-05 · NCT06774079 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer Prevention, Colorectal AdenomaRecruiting
Est. primary completion 2027-03-31 · NCT07095517 · CT.gov ↗
What to watch
April 2027 (1)
Phase 4Cardiovascular DiseasesNot yet recruiting
Est. primary completion 2027-04 · NCT07483801 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Metabolic Alcohol-associated Liver Disease, Alcohol Use DisorderRecruiting
Est. primary completion 2027-07-30 · NCT07046819 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Idiopathic Intracranial Hypertension (IIH)Recruiting
Est. primary completion 2027-08 · NCT07191873 · CT.gov ↗
What to watch
September 2027 (2)
Phase 4Pouch, Ileal, Pouches, Ileoanal, Bowel Diseases, InflammatoryRecruiting
Est. primary completion 2027-09 · NCT07756359 · CT.gov ↗
What to watch
Phase 2Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, SevereRecruiting
Est. primary completion 2027-09-30 · NCT06651177 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Aging, LONGEVITY 1Recruiting
Est. primary completion 2027-11 · NCT07220473 · CT.gov ↗
What to watch
December 2027 (2)
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-15 · NCT06657209 · CT.gov ↗
What to watch
Phase 2Type 1 Diabetes MellitusRecruiting
Est. primary completion 2027-12-31 · NCT06820281 · CT.gov ↗
What to watch
2028 (16)
January 2028 (2)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07605247 · CT.gov ↗
What to watch
Phase 2/3Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes MellitusRecruiting
Est. primary completion 2028-01 · NCT07284511 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Smoking Cessation, Smoking BehaviorsRecruiting
Est. primary completion 2028-03 · NCT07602699 · CT.gov ↗
What to watch
Phase 2Hormone-receptor-positive Breast Cancer, Early Breast CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07676331 · CT.gov ↗
What to watch
Phase 2Cannabis Use DisorderNot yet recruiting
Est. primary completion 2028-03-15 · NCT07468552 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Longevity, Preventive Medicine, Biological AgeingEnrolling by invitation
Est. primary completion 2028-04 · NCT07906041 · CT.gov ↗
What to watch
Phase 2Prostate Carcinoma, Recurrent Prostate CarcinomaRecruiting
Est. primary completion 2028-04-09 · NCT07202247 · CT.gov ↗
What to watch
May 2028 (4)
Phase 2Crohn Disease (CD)Recruiting
Est. primary completion 2028-05 · NCT06976853 · CT.gov ↗
What to watch
Phase 1Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic ComorbiditiesNot yet recruiting
Est. primary completion 2028-05-01 · NCT07812636 · CT.gov ↗
What to watch
Phase 2Central Centrifugal Cicatricial Alopecia (CCCA)Recruiting
Est. primary completion 2028-05-25 · NCT07734870 · CT.gov ↗
What to watch
Phase 2/3Acute Ischemic Stroke (AIS)Recruiting
Est. primary completion 2028-05-31 · NCT07734792 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Cannabis Use DisorderNot yet recruiting
Est. primary completion 2028-06-30 · NCT07265752 · CT.gov ↗
What to watch
July 2028 (3)
Phase 4Neuropathy, Small Fiber, Diabete MellitusNot yet recruiting
Est. primary completion 2028-07-01 · NCT07706088 · CT.gov ↗
What to watch
Phase 2Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; StatusRecruiting
Est. primary completion 2028-07-31 · NCT07573163 · CT.gov ↗
What to watch
Phase 3Cannabis Use Disorder, Moderate, Cannabis Use Disorder, SevereNot yet recruiting
Est. primary completion 2028-07-31 · NCT07671248 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism, Schizophrenia Disorders …Recruiting
Est. primary completion 2028-08-01 · NCT06939088 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2029-04-30 · NCT06246799 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Lipodystrophy, PartialRecruiting
Est. primary completion 2029-09 · NCT07091734 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Recruiting
Est. primary completion 2030-03-15 · NCT07527910 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri, PapilledemaNot yet recruiting
Est. primary completion 2030-05-01 · NCT07946315 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Lung CancerRecruiting
Est. primary completion 2030-06 · NCT07782359 · CT.gov ↗
What to watch
August 2030 (1)
Phase 3Metabolic Dysfunction-Associated Steatotic Liver DiseaseRecruiting
Est. primary completion 2030-08 · NCT07165028 · CT.gov ↗
What to watch
2031 (2)
July 2031 (1)
Phase 2Methamphetamine Use DisorderRecruiting
Est. primary completion 2031-07-01 · NCT07825857 · CT.gov ↗
What to watch
December 2031 (1)
Phase 1Alcohol Use Disorder (AUD)Recruiting
Est. primary completion 2031-12-31 · NCT07559500 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalFDA approves Mounjaro to reduce cardiovascular risk in type 2 diabetes
US, FDA · Source ↗
27 August 2026ApprovalFDA Boxed Warning on Mounjaro (NDA215866)
US, FDA · FDA · Source ↗
20 December 2024ApprovalFDA approves Zepbound for obstructive sleep apnea in adults with obesity
US, FDA · Source ↗